31810 The National Paediatric Alopecia Areata Registry in Russia: An overview

Abstract

92 patients aged 2 to 17 years were included. 71 patients had at least 1 concomitant disease, the most common was atopic dermatitis (n = 31). Thyroid disorders was also a frequent concomitant diagnosis (n = 11). In addition, 3 patients had vitiligo, 3 more had psoriasis and 2 had celiac disease. All patients are assessed using the “Scalp, Body, and Nail classification of alopecia areata.” Half of the observed patients suffer from total hair loss, s1 – in 18%, s2 – in 11%, s3 – in 7%, s4a – in 6%, s4b – in 8 % of patients. Among all patients, 23 children (17 with universal form and 6 with local form) receive off-label therapy with tofacitinib for a period of 16 ± 7.5 weeks. On the background of tofacitinib therapy, a positive effect was observed in all patients with alopecia areata: the SALT index in 4 out of 6 patients decreased from 45 ± 11.9 to 10 ± 4.7 points, and in 2 patients - 0 points. While taking tofacitinib, 32 of 46 patients with total and universal forms of alopecia improved their condition. Conclusions: Further study of the features of alopecia areata and the accumulation of data on the efficacy and safety of systemic therapy in children is required.